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simple and useful tool for quantifying and exploring the (com-
bined) uncertainty associated with decision-making about adopt-
ing guidelines and implementation strategies and, therefore, for
informing decisions about efﬁcient resource allocation to change
clinical practice.
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OBJECTIVES: Estimation of cost-of-illness typically involves
the analysis of skewed medical costs that include large outliers.
Log transformations are frequently used to overcome these
problems. Linear regression models (OLS) are then applied to
the transformed data. The estimated model coefﬁcients are
retransformed back to the linear scale using the smearing
approach. Implementing this approach in statistical packages
requires customized programming. We propose an alternative to
using log transformations: Generalized Linear Models (GLM)
with a log link function. We compare the performance of both
models in estimating cost-of-illness. METHODS: We derived
data from a large administrative database representing 143,593
discharges from 39 US hospitals from January 2004 to Decem-
ber 2005. We estimated total medical costs among hospitalized
patients attributable to hyponatremia. Using a cross-validation
approach, we compared the performance of two models: log
transformed OLS with smearing and GLM with a log link func-
tion and a normal error distribution. We used the Root Mean
Squared Error (RMSE) and the Mean Absolute Error (MAE) to
assess model performance. Covariates in both models included
patient age, gender, race, geographic region, Deyo-Charlson
comorbidity index, primary diagnosis, teaching status of hospi-
tal, and admission source. All analyses were contacted using
SAS®. RESULTS: The GLM with log-link and a normal error
distribution had both the smallest RMSE (23,688) and MAE
(11,304) compared to the log transformed OLS with smearing
(24,057 and 11,392, respectively). Furthermore, by using GLM,
there was no need to compute a retransformation estimate, since
the log link function relates the response mean to the original
scale. CONCLUSIONS: In this cross-validation study, GLM
outperformed OLS with smearing. GLM is easier to implement
using SAS® with no need for retransformation estimates. Because
of its ease of use and statistical accuracy, GLM is a useful alter-
native to log-transformed OLS models with smearing, when
estimating cost-of-illness.
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OBJECTIVES: Reimbursement decisions are often supported by
economic evaluations based on randomised controlled trials
(RCTs). A problem with RCTs is that they usually deviate from
daily practice. Hence, reimbursement decisions are based on
perfect-world assessments of cost-effectiveness. In daily practice,
the technology is likely to be less cost-effective for instance due to
lower compliance. To make real-world reimbursement decisions,
factors that potentially inﬂuence the cost-effectiveness should be
considered. These factors are implementation factors, and sto-
chastic in nature. This study presents a framework that incorpo-
rates the implementation of a technology directly into the
economic evaluation, thus anticipating on potentially less than
perfect implementation. This results in real-world economic
evaluations. METHODS: The framework allows for a stepwise
consideration of the net beneﬁt (NB) of a technology in different
states of the world: 1) perfect-world (NB under perfect imple-
mentation); 2) real-world (NB under expected implementation);
and 3) improved-world (NB after intervention to improve imple-
mentation). Step 1 tells us whether the technology could be
cost-effective. Step 2 gives us the real world cost-effectiveness.
The difference between the NB of step 1 and 2 gives the upper
bound of the value of improving implementation. Step 3 tells us
whether it is cost-effective to invest in speciﬁc interventions to
improve implementation. The implementation factors are sto-
chastic, therefore in each step parameter uncertainty is addressed
in probabilistic sensitivity analyses, and the value of reducing
uncertainty is examined in value of information analyses.
RESULTS: As a case we used a Markov model that examines the
cost-effectiveness of direct hearing aid provision versus provision
by referral. Two stochastic implementation parameters were
incorporated: patient compliance and professional uptake. The
upper bound of the value of improving implementation was €50
million (patient compliance), €23 (professional uptake) and €72
million in total. This suggests that implementation interventions
may be valuable (results presented at the conference).
METHODS: CONCLUSIONS: This framework allows for real-
word economic evaluations to inform policy decisions.
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In 1996 the Washington Panel controversially recommended
valuing productivity costs (PC) in terms of QALYs. While this
recommendation was criticised, the Panel’s assumption, that
respondents in health state valuation (HSV) exercises take
income losses into account, could not be countered since there
was no evidence regarding what people consider in HSV exer-
cises. If they do consider income losses and if this changes HSV’s,
then all past economic evaluations that have included PC in the
numerator may have double counted these costs. Alternatively, if
respondents do not consider income losses then all past economic
evaluations that have not included PC in the numerator have
failed to account for sizeable societal costs. OBJECTIVES: To
recapture the debate surrounding the appropriate method for
including PC in health economic evaluations, to identify empiri-
cal evidence addressing the assumptions made by the Washington
Panel and to recommend a research agenda for the future.
METHODS: In this review we ﬁrst present and discuss the
human capital and friction cost approaches for capturing PC.
Then, the Washington Panel approach is highlighted and dis-
cussed. Next, we identify, outline and critically appraise the
existing empirical studies that attempt to address the assumption
that respondents to HSV exercises take income effects into
account. Finally, we outline a research agenda for the future that
will help to determine the most appropriate method for including
PC. RESULTS AND CONCLUSIONS: Only six empirical
studies were identiﬁed. The studies differ substantially in
methods and results and drawing general conclusions from them
is difﬁcult. Overall, it seems that not explicitly mentioning the
inclusion of income will induce a minority of respondents to
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include these effects and this appears not to inﬂuence results in
general. More empirical work is needed, using generic instru-
ments, larger and more relevant samples, and perhaps using the
interview method of administration.
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OBJECTIVES: Expensive drugs for rare disorders (EDRDs;
“orphan drugs”) do not usually meet widely applied cost-
effectiveness benchmarks (“lambdas”). Adopting the standard
decision rules of the logic cost-effectiveness cannot be reconciled
with granting reimbursement status for many EDRDs and would
inevitably deprive patients with very rare disorders from any
chance to get access to effective treatment, given the high ﬁxed /
low variable cost structure of the pharmaceutical industry. On
the other hand, public policies have been established to provide
incentives to support development of orphan drugs. This (and
some further observations) suggests a serious mismatch between
the logic of cost-effectiveness and societal preferences. Decision-
makers have responded; for instance, the National Institute for
Health and Clinical Excellence (NICE) attempts to deﬁne a
special subcategory of “ultra-orphans”—while maintaining that
budgetary impact analysis is not part of its appraisal decisions
(but limited to implementation support). This policy, however,
does not appear to adequately address the underlying problem.
METHODS: First, “ultra-orphans” are not a distinct, well-
deﬁned category—they rather represent one extreme of a
continuous spectrum, and “orphan drugs” and some cancer
treatments pose the same fundamental problem. Second, size of a
patient population eligible for treatment is directly linked to
budgetary impact (and hence the opportunity for manufacturers
to recoup ﬁxed costs), whereas the logic of cost-effectiveness is
impaired by not taking into account the size of the numerator
and the denominator of the incremental cost-effectiveness ratio
(ICER), which has been described as “the silence of the lambda.”
Policy makers might address these issues by explicitly taking
budgetary impact into account when deciding on maximum
reimbursement prices or by price-volume agreements. RESULTS:
Both approaches, albeit perhaps pragmatic, cannot satisfy from a
theoretical economic perspective. CONCLUSIONS: Rigorous
normative analysis and empirical research are required to further
explore the mapping of individual health-related utilities into
societal preferences (willingness-to-pay).
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OBJECTIVES: To determine if and to what extent records
obtained from PBM pharmacy claims differ from source docu-
ments obtained directly from pharmacy providers. Also this
study sought to explore possible associations between patient,
pharmacy beneﬁt, and pharmacy provider characteristics and the
likelihood a patient would have missing prescription claims.
METHODS: This study used a cross sectional survey of 1,484
patients residing in a single state with a common pharmacy
beneﬁt. Patient proﬁles describing all prescriptions ﬁlled in a
pharmacy between January 1, 2002 through June 30, 2002 of
these patients were requested directly from their pharmacy pro-
viders. Logistic regression was used to explore the factors asso-
ciated with a person receiving a prescription that did not appear
on the PBM claims. RESULTS: Of the 1484 eligible recipients
sampled, proﬁles were obtained for 323 (22%) persons and there
were analyzable proﬁles for 315 (21%) persons. Of those 2,977
prescriptions ﬁlled for the 315 persons, 207 (7.0%) were missing
from the claims ﬁles indicating that 93% were captured. Pre-
scription drugs such as iron products, digoxins, diuretics, sulfo-
nylureas, and antigout were more likely to be missing from the
PBM claims. Only prescription volume consistently inﬂuenced
the likelihood a patient would have a missing prescription from
the PBM claims (OR = 1.08; 95% CI: 1.05–1.12). CONCLU-
SIONS: Claims obtained from pharmacy beneﬁt companies
capture approximately 93% of prescription records when veri-
ﬁed with records obtained from pharmacy providers. The rate of
missing records from PBM claims does not appear to be mean-
ingfully inﬂuenced by most ﬁnance based pharmacy beneﬁt
design features, however, certain drugs available over the counter
and less expensive drugs may have less complete claims records
compared to other classes of drugs. Higher prescription utilizers
are more likely to have prescription records ﬁlled that are not
captured by PBMs.
CONCEPTUAL PAPERS & RESEARCH ON
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OBJECTIVE: The core of a cost effectiveness model should be
guided by the underlying disease process, natural history and
how particular interventions impact on disease. The development
of conceptual models within PRO research is based on the same
rationale. The objective of this study was to explore the overlap
between cost effectiveness modelling and conceptual models for
PROs, using AD as an example. METHODS: A conceptual
model of AD was reviewed alongside a cost effectiveness model
by a team of PRO researchers and health economists. Areas of
commonality and divergence were documented and discussed.
RESULTS: Points of overlap were identiﬁed which included the
impact of AD on day to day functioning of the patient and
associated caregiver burden. This will inﬂuence the ability of the
caregiver to work and impact on other resource utilisation. This
may, also have an impact on the time to institutionalisation,
which is a major ﬁnancial burden in AD. One major area of
divergence is the emphasis in economic models on the use of
generic quality of life data; whereas conceptual models are
commonly developed to measure disease speciﬁc PRO burden.
CONCLUSIONS: The commonalities between PRO conceptual
models and health economic models indicates the potential for
developing PRO and HE models simultaneously. This is likely to
increase the validity of each of the models as well as having a
positive impact on related research e.g. through the development
of health state utilities. As a next step we are prospectively
developing a conceptual model of disease which is speciﬁcally
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